纳曲酮结构式
|
常用名 | 纳曲酮 | 英文名 | naltrexone |
---|---|---|---|---|
CAS号 | 16590-41-3 | 分子量 | 341.40 | |
密度 | 1.5±0.1 g/cm3 | 沸点 | 558.1±50.0 °C at 760 mmHg | |
分子式 | C20H23NO4 | 熔点 | 168-170ºC | |
MSDS | N/A | 闪点 | 291.4±30.1 °C | |
符号 |
GHS02, GHS06, GHS08 |
信号词 | Danger |
纳曲酮用途Naltrexone 是 Opioid receptor 的拮抗剂。Naltrexone 在体内抑制细胞增殖。Naltrexone 通过干扰细胞信号和改变免疫系统来抑制肿瘤生长。 |
中文名 | 纳曲酮 |
---|---|
英文名 | naltrexone |
中文别名 | 17-(环丙甲基)-4,5-环氧-3,14-二羟基吗啡烷-6-酮 | 纳屈酮 |
英文别名 | 更多 |
描述 | Naltrexone 是 Opioid receptor 的拮抗剂。Naltrexone 在体内抑制细胞增殖。Naltrexone 通过干扰细胞信号和改变免疫系统来抑制肿瘤生长。 |
---|---|
相关类别 | |
参考文献 |
[7]. Naltrexone |
密度 | 1.5±0.1 g/cm3 |
---|---|
沸点 | 558.1±50.0 °C at 760 mmHg |
熔点 | 168-170ºC |
分子式 | C20H23NO4 |
分子量 | 341.40 |
闪点 | 291.4±30.1 °C |
精确质量 | 341.162720 |
PSA | 70.00000 |
LogP | 1.80 |
蒸汽压 | 0.0±1.6 mmHg at 25°C |
折射率 | 1.709 |
储存条件 | 库房通风低温干燥,与氧化剂,食品分开储运 |
符号 |
GHS02, GHS06, GHS08 |
---|---|
信号词 | Danger |
危害声明 | H225-H301 + H311 + H331-H370 |
警示性声明 | P210-P260-P280-P301 + P310-P311 |
危害码 (欧洲) | F,T |
风险声明 (欧洲) | 11-23/24/25-39/23/24/25 |
安全声明 (欧洲) | 16-36/37-45 |
危险品运输编码 | UN1230 - class 3 - PG 2 - Methanol, solution |
纳曲酮上游产品 9 | |
---|---|
纳曲酮下游产品 6 | |
Novel orally available salvinorin A analog PR-38 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.
J. Pharmacol. Exp. Ther. 350(1) , 69-78, (2014) The opioid and cannabinoid systems play a crucial role in multiple physiological processes in the central nervous system and in the periphery. Selective opioid as well as cannabinoid (CB) receptor ago... |
|
Desensitization of functional µ-opioid receptors increases agonist off-rate.
Mol. Pharmacol. 86(1) , 52-61, (2014) Desensitization of µ-opioid receptors (MORs) develops over 5-15 minutes after the application of some, but not all, opioid agonists and lasts for tens of minutes after agonist removal. The decrease in... |
|
Treatment of alcohol dependence: recent progress and reduction of consumption.
Minerva Med. 105(6) , 447-66, (2014) Alcohol dependence (AD) is a major public health problem. Currently, three drugs for the treatment of AD have been approved by both the European Medicines Agency (EMA) and the Food and Drug Administra... |
Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5α)- |
Trexonil |
NeMexin |
(1S,5R,13R,17S)-4-(Cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0.0.0]octadeca-7(18),8,10-trien-14-on |
Depotrex |
ReVia |
en1939 |
Naltrel |
en1639 |
Naltrexone |
Vivitrol |
(5α)-17-(Cyclopropylmethyl)-3,14-dihydroxy-4,5-epoxymorphinan-6-one |
Antaxone |
trexan |
(1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0.0.0]octadeca-7(18),8,10-trien-14-one |
(1S,5R,13R,17S)-4-(cyclopropylméthyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0.0.0]octadéca-7(18),8,10-trién-14-one |
celupan |
En 1639A |
Um-792 |
(5a)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one |
Nalorex |
Depade |